Trial record 1 of 1 for:    oc-eg-303
Previous Study | Return to List | Next Study

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02603705
Recruitment Status : Completed
First Posted : November 13, 2015
Last Update Posted : March 5, 2018
Information provided by (Responsible Party):
Egalet Ltd

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.

Condition or disease Intervention/treatment Phase
Moderate-to-severe Chronic Noncancer Pain Drug: Oxycodone extended-release Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 281 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain
Actual Study Start Date : March 7, 2016
Actual Primary Completion Date : June 15, 2017
Actual Study Completion Date : June 15, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Oxycodone extended-release
Egalet abuse-deterrent, extended-release oxycodone tablet
Drug: Oxycodone extended-release

Primary Outcome Measures :
  1. Incidence of TEAEs during the Open-label Treatment Period, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Findings of the Brief Pain Inventory-Short Form (BPI-SF) during the Open-label Treatment Period [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Is a man or woman between 18 and 75 years of age.
  • Has a clinical history of moderate-to-severe chronic noncancer pain ≥6 months.
  • Has required opioid therapy for at least 14 days prior to Screening at a dose between 20 mg and 160 mg (inclusive) oxycodone/day (or opioid equivalent), and will, in the opinion of the investigator, continue to require opioid therapy (between 20 mg and 240 mg oxycodone/day, inclusive) for management of moderate-to-severe pain for the duration of the study.
  • Has pain either not adequately controlled on current opioid regimen, requires a change of opioid due to tolerability of current opioid regimen or in the opinion of the investigator, would benefit from changing opioid for another reason.
  • Has stable health, as determined by the investigator.
  • If female, the patient is currently not pregnant, not breast-feeding, nor attempting to become pregnant (for 30 days before screening through the duration of the study), or is of non-childbearing potential.
  • Other Criteria Apply

Exclusion Criteria:

  • Has cancer-related pain.
  • Is receiving >240 mg oxycodone daily (or opioid equivalent) within 30 days before Screening.
  • Has a history of attempted suicide.
  • Has used a spinal infusion pump within 6 months before Screening.
  • Has clinically unstable cardiac disease (including atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia) and/or respiratory disease (including chronic obstructive pulmonary disease or sleep apnea).
  • Has positive urine toxicity screen for drugs of abuse (with the exception of prescribed medications).
  • Has positive result for tetrahydrocannabinol (even if legally prescribed).
  • Has current (or history of within the last 12 months) drug dependence or substance abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision criteria (excluding nicotine).
  • Other Criteria Apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02603705

  Hide Study Locations
United States, Alabama
Site 334
Huntsville, Alabama, United States, 35801
United States, Arizona
Site 328
Tucson, Arizona, United States, 85712
United States, Florida
Site 332
Jacksonville, Florida, United States, 32257
Site 340
Miami Gardens, Florida, United States, 33169
Site 320
Plantation, Florida, United States, 33317
Site 302
Tampa, Florida, United States, 33603
Site 315
Tampa, Florida, United States, 33613
Site 310
Winter Haven, Florida, United States, 33880
United States, Georgia
Site 316
Dawsonville, Georgia, United States, 30534
Site 311
Marietta, Georgia, United States, 30060
United States, Illinois
Site 336
Bloomington, Illinois, United States, 61701
Site 345
Blue Island, Illinois, United States, 60406
United States, Indiana
Site 304
Evansville, Indiana, United States, 47714
Site 325
Valparaiso, Indiana, United States, 46383
United States, Kansas
Site 321
Overland Park, Kansas, United States, 66210
Site 342
Wichita, Kansas, United States, 67205
United States, Louisiana
Site 329
New Orleans, Louisiana, United States, 70114
United States, Massachusetts
Site 326
Quincy, Massachusetts, United States, 02169
United States, Missouri
Site 303
Saint Louis, Missouri, United States, 63141
United States, Nevada
Site 306
Las Vegas, Nevada, United States, 89119
United States, New Jersey
Site 313
Belvidere, New Jersey, United States, 07823
Site 346
Blackwood, New Jersey, United States, 08012
United States, New York
Site 323
Hartsdale, New York, United States, 10530
United States, North Carolina
Site 338
Mooresville, North Carolina, United States, 28117
United States, Ohio
Site 333
Cincinnati, Ohio, United States, 45212
Site 343
Cleveland, Ohio, United States, 44122
Site 308
Huber Heights, Ohio, United States, 45424
Site 347
Kettering, Ohio, United States, 45429
United States, Oklahoma
Site 335
Oklahoma City, Oklahoma, United States, 73112
United States, Oregon
Site 312
Eugene, Oregon, United States, 97401
United States, Pennsylvania
Site 322
Duncansville, Pennsylvania, United States, 16635
Site 324
Wyomissing, Pennsylvania, United States, 19610
United States, South Carolina
Site 344
Myrtle Beach, South Carolina, United States, 29588
Site 314
Summerville, South Carolina, United States, 29485
United States, Tennessee
Site 341
New Tazewell, Tennessee, United States, 37825
United States, Texas
Site 318
Austin, Texas, United States, 78731
Site 330
Dallas, Texas, United States, 75231
Site 309
San Antonio, Texas, United States, 78218
United States, Utah
Site 331
West Jordan, Utah, United States, 84088
Sponsors and Collaborators
Egalet Ltd

Responsible Party: Egalet Ltd Identifier: NCT02603705     History of Changes
Other Study ID Numbers: OC-EG-303
First Posted: November 13, 2015    Key Record Dates
Last Update Posted: March 5, 2018
Last Verified: March 2018

Keywords provided by Egalet Ltd:
chronic pain
non cancer pain
moderate to severe

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents